Reply to Puxeddu et al.
From the Authors:
We thank Puxeddu and colleagues for their interest in our paper and for opening a dialogue regarding the role of CD71-expressing airway macrophages (AMs) in interstitial lung disease (ILD) (1) . Indeed, it is interesting that the authors found a similar population of CD71 2 AMs in a second cohort of patients with idiopathic pulmonary fibrosis (IPF), further validating our findings. The authors describe a level of CD71 2 AMs in a group of patients with non-IPF ILD comparable to that observed in patients with IPF. These data raise the question of whether CD71 2 AMs may be an important pathogenic component of IPF as well as other fibrotic lung diseases.
To determine whether the proportions of CD71-expressing AMs were altered during non-IPF ILD, we examined BAL samples from a cohort of patients with hypersensitivity pneumonitis (n = 18), respiratory bronchiolitis-associated ILD (n = 2), sarcoidosis (n = 2), or undifferentiated connective tissue disease (n = 5), and used a multicolor flow-cytometry gating strategy identical to that described in our initial publication (1) . We found that in patients with non-IPF ILD, there was an increase in the proportion of CD71 2 AMs compared with healthy control subjects, and furthermore, the proportions of these populations were similar to those found in patients with IPF ( Figure 1 ). One of the key findings of our original study is that CD71 2 AM status was an independent predictor of survival in patients with IPF. Importantly, in this non-IPF group, there was only one death over the period investigated, so it was not possible to investigate the relationship between CD71 2 AMs and mortality in this cohort.
We agree that further studies on the role of CD71 in the pathogenesis of fibrotic lung disease are needed to confirm our observations, and we thank the authors for adding to our findings. n Author disclosures are available with the text of this letter at www.atsjournals.org. To the Editor:
Translational research is essential to develop strategies for the treatment of pulmonary arterial hypertension (PAH) using animal models that reproduce the severity, the progressive nature, and the resistance to treatment of human PAH, including severe arterial remodeling and progressive right ventricular (RV) failure (1). We read with interest the letter by Kojonazarov and colleagues, who propose to have found "severe emphysema in the SU5416/hypoxia (SuHx) rat model of pulmonary hypertension" (2) . The authors report that Wistar-Kyoto rats exposed to the combination of vascular endothelial growth factor receptor 2 (VEGFR2) inhibition by SU5416 and chronic hypoxia had moderately increased right ventricular systolic pressure (RVSP) and RV mass compared with normoxic untreated animals (2) . They applied in vivo micro-computed tomography (CT) to demonstrate an increase in lung volume and a decrease in lung density, as well as an unaltered amount of lung tissue, but an increased air-to-tissue ratio; they claim that these findings were confirmed by histologic analysis, including mean linear intercept as surrogate of emphysema (2) . Indeed, SU5416 has been previously shown to induce emphysema in normoxia (3), but this required repetitive SU5416 dosing (three times per week over 3 wk) and occurred more predominantly in rats younger than 4 weeks of age (Norbert Voelkel, M.D., written communication, 2019). In addition, emphysema could be negated, at the cost of the development of severe angioproliferative hypertension, by concomitant exposure to hypoxia (4).
The SuHx model, which combines a one-time subcutaneous injection of Sugen (SU5416), which blocks VEGFR2 but also other tyrosine kinases, with 2-4 weeks of hypoxia (5-7), is the most accepted rodent model for PAH. Although several modifications of the SuHx model exist, the most commonly used study design is the one-time injection of 20 mg/kg SU5416 subcutaneously in 6-to 8-week-old Sprague-Dawley rats (body weight 180-200 g), followed by 3 weeks hypoxia (10% oxygen), and subsequently a 1-to 10-week period in room air, until heart-lung function and morphology is assessed.
Experiments in male Sprague-Dawley rats demonstrated that RVSP increases over 90 mm Hg in response to SuHx after 3 (5, 6) or 4 weeks of hypoxia (7); it then decreases somewhat in some studies, but remains elevated at 73 mm Hg (7), 91 mm Hg (6), and 96 mm Hg upon return to normoxia for an additional 4 (7), 6, or 10 weeks (5, 6), respectively (Table 1) . Importantly, at 6 (6) and 10 weeks (5) after the end of hypoxia, plexiform lesions that are very similar to such lesions in human idiopathic PAH were frequently found in SuHx rats (5, 6) , in addition to concentric medial hypertrophy of small-and medium-sized pulmonary arteries (6) . Legchenko and colleagues demonstrated that RV failure develops between 1 and 6 weeks after the end of 3 weeks of hypoxia in SuHx rats, together with progression of pulmonary vascular disease, loss of peripheral pulmonary arterioles, and a metabolic switch in the right ventricle (6) .
The advantages of the SuHx rat versus most other rat models of PAH such as monocrotaline were highlighted by a group of experts, and include the intensification of the vascular remodeling process, leading to the appearance of human-like plexiform lesions, and the virtual unresponsiveness to current PAH treatments, correlating well with the common unresponsiveness of PAH to therapy in humans (1) . Importantly, "severe emphysema" has not been observed previously in the SuHx rat model of PAH. Based on the report by Kojonazarov and colleagues (2), we have not only conducted a search of the literature but also analyzed lung histology from different SuHx rat studies in established laboratories ( Table 1 and Figure 1 ). In contrast to Kojonazarov and colleagues, we did not find any severe or even moderate emphysema in any of the SuHx models analyzed (Figure 1 and Table 1 ). Mean linear intercept (MLI) as a surrogate for alveolar enlargement was not significantly different in SuHx versus untreated control lungs from Sprague-Dawley rats obtained from Charles River (Figures 1A and 1B) . The Stewart group measured MLI in Sprague-Dawley rats obtained from Harlan, and found a mild (18%) increase in MLI in SuHx 
